Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …

Purpose Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common.
Genetic biomarkers have been used to predict these adverse events, but their utility is …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Gastric cancer remains one of the deadly diseases with poor prognosis. New classification
of gastric cancers based on histologic features, genotypes and molecular phenotypes helps …

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …

Background Pathogenic variants of the DPYD gene are strongly associated with grade≥ 3
toxicity during fluoropyrimidine chemotherapy. We conducted a systematic review and meta …

Human genomes are diploid and, for their complete description and interpretation, it is
necessary not only to discover the variation they contain but also to arrange it onto …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …